Abstract
In a BALB/c murine intra-nasal model of infection for Francisella tularensis SCHU S4 (F. tularensis) 20
infection, we demonstrate during a time course that pro-inflammatory cytokines and the damage 21 associated molecular pattern, HMGB1, were not significantly elevated above naive levels in tissue or 22 sera until 72h post-infection. HMGB1 was identified as a potential therapeutic target that could extend 23 the window of opportunity for the treatment of tularaemia with antibiotics. 24
Antibodies to HMGB1 were administered in conjunction with a delayed/sub-optimal levofloxacin 25 treatment of F. tularensis. We found in the intranasal model of infection that treatment with anti-26 HMGB1 antibody, when compared to an isotype IgY control antibody, conferred a significant 27 survival benefit and decreased bacterial loads in the spleen and liver but not the lung (primary loci of 28 infection) four days into infection. We also observed an increase in the production of interferon-γ in 29 all tested organs. 30
This data demonstrates that treatment with anti-HMGB1 antibody is beneficial in enhancing the 31 effectiveness of current antibiotics in treating tularemia. Strategies, of this type, involving antibiotics 32 in combination with immuno-modulatory drugs are likely to be essential for the development of a 33
Introduction

37
Francisella tularensis is a Gram-negative intracellular bacterium that has the ability to infect several 38 different types of cell and is the causative agent of the disease tularemia [1, 2] . Four subspecies of F. Groups of mice receiving either the anti-HMGB1 or the isotype control Ab were culled at 96 h to 114 examine the effects of the treatment alone. Additionally, a second group of mice received a 115 combination therapy of the antibody and the antibiotic levofloxacin (Table 1) . In these groups the 116 antibiotic was administered once daily via the intraperitoneal route at 40 mg / kg commencing 96 h p.i 117 and continuing for a period of seven days. Where mice were culled, they were exsanguinated using 118 cardiac puncture following terminal anaesthesia. Blood was extracted as above and placed into 1.5 ml 119 eppendorf tubes. Lungs, spleen and liver were removed and placed into universal tubes filled with 2 120 ml of PBS. In these studies we demonstrate that during an intra-nasal BALB/c mouse model of F. tularensis 225 SCHU S4 that there is an absence of pro-inflammatory cytokines during the first 2 days of infection. Preliminary studies have demonstrated that anti-HMGB1 antibodies could protect the host following 250 lethal LPS exposure and that the efficacy of the therapy was dose dependent [30] . 251
In these studies we sought to determine whether controlling/dampening down the "overactive" 252 inflammatory response, by targeting HMGB1, was a suitable strategy to increase the effectiveness of 253 antibiotic treatments. Our study utilized an adapted version of a previously published F. tularensis 254 levofloxacin antibiotic model [13] , to test our hypothesis of whether anti-HMGB1 Ab therapy could 255 extend the window for successful antibiotic treatment and thus increase overall host survival. We used 256 a sub-optimal antibiotic dosing regimen (commencing antibiotic treatment at 96 h for a total of 7 257 days) to establish whether firstly anti-HMGB1 Ab therapy could increase the antibiotic window 258 during acute disease and secondly whether the therapy could aid in bacterial clearance. The most surprising and interesting data generated in these studies was the increase in IFN-γ in anti-270 HMGB1 Ab treated groups compared to isotype control treated mice. In all three independent 271 experiments, anti-HMGB1 Ab caused an increase in IFN-γ in all of the organs analysed. This increase 272 is unlikely to be solely due to changes in bacterial load, as bacterial burden in the lung, was not found 273 to be significantly different between treatment groups. In addition, the levels of pro-inflammatory 274 cytokines tend to correlate with bacterial load. Therefore, an increased bacterial load would also be 275 expected in the anti-HMGB1 Ab treated mice, and this is certainly not the case, since decreases in 276 bacterial load were observed in the spleen and liver post therapeutic treatment. 277
Indeed the increase in cytokines seems to be specific to IFN-γ, as quantities of MCP-1 (another pro-278 inflammatory marker) decrease in the liver following treatment with anti-HMGB1 Ab and other 279 cytokines measured remain unchanged between groups. 280
The effect on IFN-γ in these studies may indicate a further mechanism of action by the therapeutic 281 antibody, in addition to the previously mentioned, increased phagocytic ability of macrophages. 282
Indeed it is well reported that IFN-γ is critical for protection against tularaemia (38-40). Our data 283 suggests that treatment with anti-HMGB1 Ab leads to a more appropriate immune response by 284 increasing levels of IFN-γ and decreasing MCP-1. The exact role of the increase of IFN-γ in this 285
model is yet to be determined, but is most likely due to increased nitric oxide production in 286 macrophages resulting in enhanced bacterial killing. were also determined but not shown. 367
